Business

OptiNose has announced the closing of a financing round of up to $30M, which it plans to use for continued development and commercialization of its OPN-375 intranasal fluticasone as well as for additional pipeline products. The company had announced completion of its previous round of financing in August 2014. According to the company, Phase 3 development of … [Read more...] about OptiNose raises up to $30 million for development of intranasal fluticasone

InCarda Therapeutics has been issued patents in the United States, Australia and Canada covering the company's inhaled flecainide for the treatment of paroxysmal atrial fibrillation (PAF), the company said. Those patents include US patent No. 8,974,828, issued in March 2015 and titled, “Unit doses, aerosols, kits and methods for treating heart conditions by pulmonary … [Read more...] about InCarda gets patents for inhaled cardiovascular therapies

Celdara Medical and Pulmatrix have been awarded a 3-year $1.7 million Fast Track Small Business Innovation Research grant from the National Heart Lung and Blood Institute (NHLBI) for development of an inhaled therapy for the treatment of idiopathic pulmonary fibrosis, the companies said. A dry powder formulation of CM-YJH01, a biologic, will be developed using … [Read more...] about Celdara Medical and Pulmatrix get grant for inhaled biologic for idiopathic pulmonary fibrosis

GlaxoSmithKline has exercised an option for an exclusive license to develop inhaled therapies using Liquidia Techonologies' PRINT particle engineering technology, Liquidia said. The option was included in a collaboration deal the two companies signed in 2012. Liquidia also said that it has retained the right to develop an inhaled therapy independently. Upon … [Read more...] about GSK exercises option to develop inhaled drugs based on Liquidia’s PRINT technology

Teva Pharmaceutical has acquired privately held Gecko Health Innovations and its CareTRx asthma and COPD management system. CareTRx works with a monitoring device called GeckoCap that attaches to an MDI plus a mobile phone app. The acquisition comes two months after AstraZeneca announced a partnership with inhaler monitoring company Adherium. Gecko Founder and CEO … [Read more...] about Teva acquires Gecko Health Innovations

Inhaled drug developer Alexza Pharmaceuticals has hired a financial advisor "to assist in exploring strategic options to enhance stockholder value," the company said. Options being explored include selling corporate assets, a strategic business combination, or a partnership. Earlier this year, Alexza announced that it would suspend manufacturing of Adasuve inhaled … [Read more...] about Alexza considers “strategic options to enhance stockholder value”

Natesto intranasal testosterone developer Trimel Pharmaceuticals Corporation has announced that it has a new name: Acerus Pharmaceuticals Corporation. Acerus President and CEO Tom Rossi commented, “We are very excited to officially launch our new corporate identity with a name that aligns to our Company’s value proposition. The name Acerus is derived from the … [Read more...] about Trimel Pharmaceuticals changes its name to Acerus

Invion Limited, which is developing several inhaled drugs, has announced a private placement in which it is issuing 71.5 million ordinary shares at $0.014 per share to "a US institutional investor" for a total of about A$1 million. The company says that it will use the proceeds for working capital. Invion Managing Director and CEO Greg Collier commented, "Invion is … [Read more...] about Invion raises A$1 million through private placement

Aegis Therapeutics has announced that it received its first Russian patent (No. 2554814), titled, “Compositions for drug administration.” The patent covers formulations of triptans for the treatment of migraine that use Aegis’ Intravail transmucosal absorption enhancers. According to the company, the Intravail formulation results in the achievment of clinically … [Read more...] about Aegis Therapeutics gets patents for intranasal delivery of triptans

Israeli biopharmaceutical company Advanced Inhalation Therapies (AIT), which recently received orphan drug status in Europe for its inhaled nitric oxide for the treatment of cystic fibrosis, has filed with the US Securities and Exchange Commission (SEC) for an initial public offering. The company is looking to raise up to $36 million to support Phase 2 development of … [Read more...] about Advanced Inhalation Therapies files for IPO